Member Info for KilkennyTed

I'm sure Nick Tulloch has plenty of work to do. Clock is ticking.

Extract from RNS 1st April

Update on proposed move to AIM and completion of acquisition of M3 Helium

The rapid acceleration of M3 Helium's progress, including the Rost Twin and the partnership with Ritchie, has added further workstreams to the forthcoming AIM documentation and, recognising that, Mendell Helium is now targeting publication of its AIM admission document during April 2026. As previously announced, following publication of the AIM admission document, the Company will hold a general meeting (the notice period for which is 14 clear days) and accordingly admission to trading on AIM remains targeted for late April 2026. Mendell Helium will make further announcements in due course.

Also as previously announced, the Company intends to exercise the Option to acquire M3 Helium on the date of admission to trading on AIM.

Nick Tulloch, Chief Executive Officer of Mendell Helium and Chairman of M3 Helium, said: "The developments across M3 Helium's business are gaining pace and, in particular, the speed at which the Rost Twin is being drilled adds considerable confidence to the proposed Fort Dodge field development plan.

"Needless to say, we acknowledge that our move to AIM has taken longer than originally hoped but, conversely, the growth in M3 Helium's Kansas operations has not only exceeded our expectations but also remains the priority, particularly in light of the ongoing and potentially severe disruptions in global helium market. It is still too early to predict exactly how helium pricing will change as a result of the conflict in the Middle East but what is apparent is that it has exposed some fragility in both international and national helium supply chains. There will be an advantage to helium producers over the coming months in partnering with leading gas processors and we are determined to position M3 Helium prominently in the market.

"I can assure all of our investors that admission to trading on AIM is a very near term target for Mendell Helium and, alongside that, we are working to ensure that the Company continues to punch above its weight as we deal with much larger counterparties in the helium market."

(Part 2)

Industry leaders say clear and competitive federal policies are essential to attracting the private investment needed to move projects forward.

“Competitive tax treatment and access to the targeted critical minerals programs Canada has purposefully established to incentivize critical mineral development are essential for helium explorers and developers to attract the private investment needed to unlock Canada’s significant helium resource, estimated to be the fifth largest in the world,” Chris Bakker, chair of the Helium Developers Association of Canada and CEO of Avanti Helium, said. “The Government of Saskatchewan’s leadership in advancing the required policy changes is greatly appreciated.”

Treating helium the same as other critical minerals would also help make Saskatchewan the home of Canada’s first helium liquefaction facility. This type of facility is required for most high-value uses of helium and for exporting it to international markets. Building one in Saskatchewan would attract new investment, create jobs, expand export opportunities, and help ensure Canadians have a secure and dependable supply of helium, states the government in its release.

REGINA — Saskatchewan Energy and Resources Minister Chris Beaudry will lead a delegation to Ottawa next week to advocate for federal policy changes that support Saskatchewan’s helium industry, encourage private investment, and strengthen Canada’s role as a reliable supplier of helium to global markets.

The mission highlights Saskatchewan’s leadership in responsibly developing and exporting resources that support economic growth at home and help meet global demand, states a release issued by the provincial government.

Saskatchewan is Canada’s leading producer of helium, supplying about three per cent of the world’s total supply. Through the provincial Helium Action Plan, Saskatchewan is working to grow that share to 10 per cent by 2030. Saskatchewan helium producers have invested approximately $700 million in the province and continued growth will depend on a competitive policy environment that gives companies the confidence to invest and expand, according to the government.

“As a global critical minerals leader, Saskatchewan is well positioned to support industry and be a reliable, long-term supplier of helium,” Beaudry said. “Helium is essential to health care technology, advanced manufacturing, clean energy, national defence, and scientific research. Aligning federal tax treatment with other critical minerals will help unlock private investment, grow Canada’s helium sector, and ensure security of supply for domestic and international markets.”

Global helium supply chains are heavily concentrated and increasingly vulnerable to disruption. Ongoing geopolitical instability is now threatening a fifth global helium supply shortage in recent decades. Because helium is irreplaceable in most applications, supply reliability is critical, and Canada has an opportunity to respond to demand, says the government.

“The disruption of helium supply from the Middle East has reinforced the importance of building a secure, domestic helium industry,” Nicholas Snyder, chairman and CEO of North American Helium Inc., said. “Canada is growing as a helium producer but cannot remain dependent on other countries for processing capacity. Canada’s first helium liquefier is a shovel-ready critical minerals investment that would support hospitals, national defence, semiconductor manufacturing, and space exploration.”

Https://www.ad-hoc-news.de/boerse/news/ueberblick/genincode-gains-momentum-toward-key-us-regulatory-approval/69025161

GENinCode is accelerating the global commercialization of its genetic cardiovascular tests. A recent successful funding round has provided the capital needed to target the crucial US market, with a significant regulatory milestone in New York already providing positive momentum for the company's growth strategy.

Strategic US Progress and a Key Partnership

A major operational achievement was secured with the approval of the “CARDIO inCode-Score” test by the New York State Department of Health. This authorization is not only a strategic win but also financially promising, with an average reimbursement rate of approximately $500 per test establishing a clear monetization pathway. Furthermore, this state-level approval is expected to facilitate the ongoing De Novo assessment by the US Food and Drug Administration (FDA).

To scale its operations efficiently, GENinCode has entered a pivotal collaboration. A partnership established in December 2025 with Thermo Fisher Scientific covers the manufacturing and distribution of the heart test in the United States and the EMEA region. This alliance is viewed as a critical lever to drive market penetration without the need for substantial internal infrastructure investment.

Solid Financial Foundation for Growth

The company’s expansion plans are backed by a £3.9 million capital injection secured in January 2026, which exceeded the initial £3.5 million target. These proceeds are being allocated directly to the US commercialization program and to strengthening sales infrastructure in the United Kingdom and Europe.

Investors have responded to this operational progress with measured optimism. After trading at 0.977 pence in mid-March, the share price advanced to 1.08 pence by March 27. The placement of new shares at one penny apiece appears to have established a firm base for the current valuation.

Pipeline Development and Upcoming Catalysts

The focus for the coming months centers on clinical data and regulatory submissions. GENinCode plans to submit additional data to the FDA in the first quarter of 2026, a move designed to pave the way for broader US market access. Concurrently, the company is preparing for the launch of its “Thrombo inCode” test.

With its secured financing and the global reach provided by the Thermo Fisher partnership, GENinCode is building a foundation to approach break-even in the medium term. The imminent data submission to the FDA in the current quarter represents the next significant milestone on this path.

They'll probably be be released on 30th April. So outside 30 day period.

Helix Exploration PLC ("Helix") is a London-based company focused on developing helium assets in Montana, USA, with a key partnership involving Kelley Leasing Partners, LLC for transport infrastructure, as of March 2026.

Key Aspects of the Relationship and Operations:

Logistics Partnership: Helix secured its first transport asset from Kelley Leasing Partners, LLC, an Amarillo, Texas-based company. This includes a ten-cylinder jumbo tube trailer with a capacity of 156,300 standard cubic feet (SCF) of compressed helium, supporting the transition of the Rudyard Project from exploration to production.

Article from 6 weeks ago. Air Liquide might be calling Bo.

https://www.gasworld.com/story/air-liquide-strikes-long-term-helium-offtake-deal-with-qatar/2171862.article/

Air Liquide strikes long-term helium offtake deal with Qatar

By Anthony Wright

on Jan 27, 2026

Industrial gas major Air Liquide has signed a long-term sales and purchase agreement with QatarEnergy for the supply of helium. The deal reflects Qatar’s growing importance in global helium supply as new LNG projects come online.

Under the agreement, Air Liquide will offtake around 300 million cubic feet of helium per year from Qatar. The duration of the contract was not disclosed.

The deal builds on a long-standing relationship between the two companies, dating back to 2005 when QatarEnergy commissioned its first helium production facility.

"In a world where the largest supply node has just declared it cannot fulfil its contracts, that is not just an advantage - it is the advantage".

Beautiful beautiful.

At last the Board members know what it's like to be a Novacyt shareholder. In the red.

The details of the deal were known last week not sure why some are thinking the company have done some kind of backhanded deal. Purchasing a profitable company with cash plush shares seems a good deal from where i'm sitting. The board now have some skin in the game. Although it's still at a low level only 117,300 euro's worth spread over 5 non shareholder directors. With Crinelli adding 10,000 euro's worth to his existing holding. No discount at todays price.

Beautiful, beautiful.

99.999% purity helium

Cash position at 31 December 2025 was £19.2m.

So probably £18m cash at end of Feb.

Minus £4.4m to acquire Southern Cross Diagnostics

Leave approx £13.5m cash

Just as I thought Lyn Rees has resorted to buying a revenue generating business rather than generating sales themselves. You do have to wonder what the 200+ staff are doing on a daily basis. Within that staff are many different sales & marketing execs on decent salaries and yet they can only generate £20m in annual sales. They are either not very good at their jobs or the products are very hard to sell.

May as well spend the cash in bank as it was having no influence on the company valuation.

4 Months since Singer Capital were appointed joint broker. Anyone see any sign's that they are earning their monthly fees?

Key reasons for appointing a joint broker include:

Enhanced Investor Distribution & Reach: A second broker can provide complementary contacts and access to a wider investor base, helping with liquidity and share price performance. (No sign of that)

Increased Market Coverage: Different brokers often specialize in different sectors, providing broader, more comprehensive research and analysis. (Unknown)

Specialized Expertise: A joint broker can provide additional expertise, such as in specific, niche markets or with particular types of investors (e.g., private client brokers). (No sign of that)

Capital Raising Support: While one broker may lead, a joint broker can strengthen the syndicate for fundraising, bringing in more capital. (No need for capital as business has Millions in the bank. Unless looking to acquire another business. Highly likely looking at Lyn Rees history of buying business rather than building it)

Improved Attention: For smaller, high-growth companies, a second broker ensures the company receives more attention, which is crucial for trading activity. (No sign of that)

While it is more common for larger AIM companies to use joint brokers, it is still relatively rare, with only about 5% of AIM companies having more than one.

Lyn Rees likes to spout about double digit growth. That's 2 fingers to shareholders

Https://x.com/KilkennyTed/status/2014321683113349159?s=20

I first posted the link to tender in Jan 2025

Yourgene won a £2m NHS contract for NIPT. Tender was open last year & the award was finally confirmed yesterday. But the company don't feel the need to inform shareholders.

Just sums it up. Only advising the market on bad news.

https://bidstats.uk/tenders/2026/W04/863043948

Surfie what have you done? It's awake

He's taking time out. He probably thinks he deserves it after all the years of wondering when they would need cash again. No pressure on him from the board as the vast majority are Yourgene. No pressure on him from institutional investors with large stakes in the company as there are none. 99.7% retail investors.

Lesson going forward. Do not invest in a company that doesn't need investors.